Loading...
XNYS
TMO
Market cap184bUSD
Apr 02, Last price  
489.06USD
1D
1.26%
1Q
-6.41%
Jan 2017
246.61%
Name

Thermo Fisher Scientific Inc

Chart & Performance

D1W1MN
P/E
29.12
P/S
4.30
EPS
16.79
Div Yield, %
0.24%
Shrs. gr., 5y
-1.01%
Rev. gr., 5y
10.92%
Revenues
42.88b
+0.05%
2,633,027,0003,791,617,0009,746,400,00010,498,000,00010,109,700,00010,788,700,00011,725,900,00012,509,900,00013,090,300,00016,889,600,00016,965,400,00018,274,100,00020,918,000,00024,358,000,00025,542,000,00032,218,000,00039,211,000,00044,915,000,00042,857,000,00042,879,000,000
Net income
6.34b
+5.67%
223,218,000168,935,000761,100,000994,200,000850,300,0001,035,600,0001,329,900,0001,177,900,0001,273,300,0001,894,400,0001,975,400,0002,021,800,0002,225,000,0002,938,000,0003,696,000,0006,375,000,0007,725,000,0006,950,000,0005,995,000,0006,335,000,000
CFO
8.67b
+3.10%
270,913,000405,654,0001,483,500,0001,420,200,0001,659,200,0001,497,800,0001,691,000,0002,039,500,0002,010,700,0002,619,600,0002,816,900,0003,156,300,0004,005,000,0004,543,000,0004,973,000,0008,289,000,0009,543,000,0009,154,000,0008,406,000,0008,667,000,000
Dividend
Sep 13, 20240.39 USD/sh
Earnings
Apr 22, 2025

Profile

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
URL
https://www.thermofisher.com/
IPO date
Aug 27, 1980
Employees
130,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
42,879,000
0.05%
42,857,000
-4.58%
44,915,000
14.55%
Cost of revenue
26,161,000
27,081,000
26,886,000
Unusual Expense (Income)
NOPBT
16,718,000
15,776,000
18,029,000
NOPBT Margin
38.99%
36.81%
40.14%
Operating Taxes
657,000
284,000
703,000
Tax Rate
3.93%
1.80%
3.90%
NOPAT
16,061,000
15,492,000
17,326,000
Net income
6,335,000
5.67%
5,995,000
-13.74%
6,950,000
-10.03%
Dividends
(583,000)
(523,000)
(455,000)
Dividend yield
0.29%
0.25%
0.21%
Proceeds from repurchase of equity
(4,000,000)
(3,000,000)
(3,000,000)
BB yield
2.01%
1.46%
1.38%
Debt
Debt current
2,214,000
3,609,000
5,579,000
Long-term debt
29,061,000
62,616,000
57,704,000
Deferred revenue
(7,119,000)
Other long-term liabilities
5,257,000
4,642,000
4,270,000
Net debt
25,705,000
58,148,000
54,605,000
Cash flow
Cash from operating activities
8,667,000
8,406,000
9,154,000
CAPEX
(1,400,000)
(1,479,000)
(2,243,000)
Cash from investing activities
(5,841,000)
(5,142,000)
(2,159,000)
Cash from financing activities
(6,792,000)
(3,622,000)
(2,810,000)
FCF
16,863,000
16,082,000
15,780,000
Balance
Cash
5,570,000
8,077,000
8,524,000
Long term investments
154,000
Excess cash
3,426,050
5,934,150
6,432,250
Stockholders' equity
50,969,000
44,689,000
42,521,000
Invested Capital
82,776,950
80,466,850
76,441,750
ROIC
19.68%
19.75%
22.46%
ROCE
19.39%
17.86%
21.03%
EV
Common stock shares outstanding
383,000
388,000
394,000
Price
520.23
-1.99%
530.79
-3.61%
550.69
-17.47%
Market cap
199,248,090
-3.25%
205,946,520
-5.08%
216,971,860
-18.09%
EV
225,073,090
264,201,520
274,845,860
EBITDA
19,826,000
19,182,000
21,410,000
EV/EBITDA
11.35
13.77
12.84
Interest
1,390,000
1,375,000
726,000
Interest/NOPBT
8.31%
8.72%
4.03%